Brokerages predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce sales of $3.00 million for the current quarter, Zacks reports. Three analysts have provided estimates for Voyager Therapeutics’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $5.00 million. Voyager Therapeutics reported sales of $940,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 219.1%. The firm is expected to issue its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $14.01 million for the current financial year, with estimates ranging from $8.00 million to $20.00 million. For the next year, analysts forecast that the firm will post sales of $20.63 million, with estimates ranging from $8.00 million to $40.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.70). Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%.

Several analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price target on the stock. BidaskClub raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. Zacks Investment Research raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Saturday, March 2nd. Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday, February 27th. Finally, ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 23rd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Voyager Therapeutics has an average rating of “Buy” and a consensus target price of $24.00.

Shares of NASDAQ VYGR opened at $17.71 on Thursday. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $27.00. The stock has a market capitalization of $577.89 million, a price-to-earnings ratio of -6.44 and a beta of 2.58.

Large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY raised its position in shares of Voyager Therapeutics by 449.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares during the last quarter. Bank of America Corp DE raised its position in shares of Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after buying an additional 7,217 shares during the last quarter. AlphaCrest Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the fourth quarter valued at approximately $102,000. Weiss Multi Strategy Advisers LLC raised its position in shares of Voyager Therapeutics by 10.0% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 11,000 shares of the company’s stock valued at $103,000 after buying an additional 1,000 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Voyager Therapeutics by 66.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after buying an additional 4,559 shares during the last quarter. 85.86% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: What kind of dividend yield to CEF’s pay?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.